AU2023200536B2 — Methods of vitamin D treatment
Assigned to Opko Ireland Global Holdings Ltd · Expires 2025-01-16 · 1y expired
What this patent protects
The present application is directed to the use of an extended release formulation comprising 25 hydroxyvitamin D3 for the treatment of a patient with Stage 5 chronic kidney disease. The patient also has secondary hyperparathyroidism and vitamin D insufficiency, and is undergoing…
USPTO Abstract
The present application is directed to the use of an extended release formulation comprising 25 hydroxyvitamin D3 for the treatment of a patient with Stage 5 chronic kidney disease. The patient also has secondary hyperparathyroidism and vitamin D insufficiency, and is undergoing haemodialysis three times per week.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.